Craig Meiers1, Amy Taylor2, Brian Geller1, Beau Toskich3. 1. Department of Radiology, University of Florida, College of Medicine, Gainesville, FL, USA. 2. Department of Radiology, Medical College of Wisconsin, Milwaukee, WI, USA. 3. Department of Radiology, Mayo Clinic, Jacksonville, FL, USA.
Abstract
BACKGROUND: Hepatic metastatectomy and ablation are associated with prolonged survival, but not all lesions are anatomically amenable to these therapies. We evaluated safety and initial efficacy of segmental ablative transarterial radioembolization, or radiation segmentectomy (RS), as a treatment for hepatic metastases. METHODS: A single institution retrospective analysis was performed of patients with hepatic metastases, determined unamenable to resection by a multidisciplinary tumor board, treated with RS from 2015-2017. Safety parameters evaluated were pre and post procedure liver chemistry, MELD score, ALBI grade, platelet count, and adverse events using both Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 and Clavien Dindo (CD) classifications. Initial efficacy was evaluated using RECIST, mRECIST, and PERCIST criteria. RESULTS: Ten patients underwent between 1-3 RS treatments. There was no clinical treatment toxicity or significant post-treatment change in liver chemistry, MELD, or ALBI score. One patient had a CTCAE Grade 1/CD Grade 1 adverse event. All patients showed partial or complete imaging response at initial assessment (1-3 months). Seven patients demonstrated disease control at a mean of 7.1 months post treatment. Three patients developed out of field disease progression. One RS was technically unsuccessful. CONCLUSIONS: Early evaluation of segmental radioembolization suggests a safe treatment option for select patients with hepatic metastases. Initial efficacy as definitive radiotherapy with minimal toxicity is promising in anatomic locations unamenable to resection or alternative means of ablation.
BACKGROUND: Hepatic metastatectomy and ablation are associated with prolonged survival, but not all lesions are anatomically amenable to these therapies. We evaluated safety and initial efficacy of segmental ablative transarterial radioembolization, or radiation segmentectomy (RS), as a treatment for hepatic metastases. METHODS: A single institution retrospective analysis was performed of patients with hepatic metastases, determined unamenable to resection by a multidisciplinary tumor board, treated with RS from 2015-2017. Safety parameters evaluated were pre and post procedure liver chemistry, MELD score, ALBI grade, platelet count, and adverse events using both Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 and Clavien Dindo (CD) classifications. Initial efficacy was evaluated using RECIST, mRECIST, and PERCIST criteria. RESULTS: Ten patients underwent between 1-3 RS treatments. There was no clinical treatment toxicity or significant post-treatment change in liver chemistry, MELD, or ALBI score. One patient had a CTCAE Grade 1/CD Grade 1 adverse event. All patients showed partial or complete imaging response at initial assessment (1-3 months). Seven patients demonstrated disease control at a mean of 7.1 months post treatment. Three patients developed out of field disease progression. One RS was technically unsuccessful. CONCLUSIONS: Early evaluation of segmental radioembolization suggests a safe treatment option for select patients with hepatic metastases. Initial efficacy as definitive radiotherapy with minimal toxicity is promising in anatomic locations unamenable to resection or alternative means of ablation.
Authors: Kent Sato; Robert J Lewandowski; James T Bui; Reed Omary; Russell D Hunter; Laura Kulik; Mary Mulcahy; David Liu; Howard Chrisman; Scott Resnick; Albert A Nemcek; Robert Vogelzang; Riad Salem Journal: Cardiovasc Intervent Radiol Date: 2006 Jul-Aug Impact factor: 2.740
Authors: Al B Benson; Alan P Venook; Lynette Cederquist; Emily Chan; Yi-Jen Chen; Harry S Cooper; Dustin Deming; Paul F Engstrom; Peter C Enzinger; Alessandro Fichera; Jean L Grem; Axel Grothey; Howard S Hochster; Sarah Hoffe; Steven Hunt; Ahmed Kamel; Natalie Kirilcuk; Smitha Krishnamurthi; Wells A Messersmith; Mary F Mulcahy; James D Murphy; Steven Nurkin; Leonard Saltz; Sunil Sharma; David Shibata; John M Skibber; Constantinos T Sofocleous; Elena M Stoffel; Eden Stotsky-Himelfarb; Christopher G Willett; Christina S Wu; Kristina M Gregory; Deborah Freedman-Cass Journal: J Natl Compr Canc Netw Date: 2017-03 Impact factor: 11.908
Authors: Siddharth A Padia; Robert J Lewandowski; Guy E Johnson; Daniel Y Sze; Thomas J Ward; Ron C Gaba; Mark O Baerlocher; Vanessa L Gates; Ahsun Riaz; Daniel B Brown; Nasir H Siddiqi; T Gregory Walker; James E Silberzweig; Jason W Mitchell; Boris Nikolic; Riad Salem Journal: J Vasc Interv Radiol Date: 2016-11-09 Impact factor: 3.464
Authors: Ahsun Riaz; Vanessa L Gates; Bassel Atassi; Robert J Lewandowski; Mary F Mulcahy; Robert K Ryu; Kent T Sato; Talia Baker; Laura Kulik; Ramona Gupta; Michael Abecassis; Al B Benson; Reed Omary; Laura Millender; Andrew Kennedy; Riad Salem Journal: Int J Radiat Oncol Biol Phys Date: 2010-04-24 Impact factor: 7.038
Authors: Riad Salem; Andrew C Gordon; Samdeep Mouli; Ryan Hickey; Joseph Kallini; Ahmed Gabr; Mary F Mulcahy; Talia Baker; Michael Abecassis; Frank H Miller; Vahid Yaghmai; Kent Sato; Kush Desai; Bartley Thornburg; Al B Benson; Alfred Rademaker; Daniel Ganger; Laura Kulik; Robert J Lewandowski Journal: Gastroenterology Date: 2016-08-27 Impact factor: 22.682
Authors: I Kurilova; A Bendet; E K Fung; E N Petre; J L Humm; F E Boas; C H Crane; N Kemeny; T P Kingham; A Cercek; M I D'Angelica; R G H Beets-Tan; C T Sofocleous Journal: Abdom Radiol (NY) Date: 2021-02-19
Authors: M Weber; M Lam; C Chiesa; M Konijnenberg; M Cremonesi; P Flamen; S Gnesin; L Bodei; T Kracmerova; M Luster; E Garin; K Herrmann Journal: Eur J Nucl Med Mol Imaging Date: 2022-02-11 Impact factor: 9.236